Akihito Tsubota

Summary

Affiliation: Jikei University School of Medicine
Country: Japan

Publications

  1. pmc Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C
    Akihito Tsubota
    Institute of Clinical Medicine and Research, The Jikei University School of Medicine, 163 1 Kashiwa shita, Kashiwa, Chiba 277 8567, Japan
    World J Gastroenterol 18:5879-88. 2012
  2. ncbi request reprint Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato, Tokyo, Japan
    J Gastroenterol Hepatol 20:426-32. 2005
  3. doi request reprint Bovine lactoferrin potently inhibits liver mitochondrial 8-OHdG levels and retrieves hepatic OGG1 activities in Long-Evans Cinnamon rats
    Akihito Tsubota
    Institute of Clinical Medicine and Research ICMR, Jikei University School of Medicine, Kashiwa, Chiba, Japan
    J Hepatol 48:486-93. 2008
  4. pmc Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study
    Akihito Tsubota
    Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163 1 Kashiwa shita, Kashiwa, Chiba 277 8567, Japan
    World J Gastroenterol 14:7220-4. 2008
  5. doi request reprint IQGAP1 and vimentin are key regulator genes in naturally occurring hepatotumorigenesis induced by oxidative stress
    Akihito Tsubota
    Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163 1 Kashiwa shita, Kashiwa, Chiba 277 8567, Japan
    Carcinogenesis 31:504-11. 2010
  6. pmc Peginterferon and ribavirin treatment for hepatitis C virus infection
    Akihito Tsubota
    Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163 1 Kashiwa shita, Kashiwa, Chiba, Japan
    World J Gastroenterol 17:419-32. 2011
  7. ncbi request reprint Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 75:27-34. 2005
  8. ncbi request reprint Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Oncology 65:204-10. 2003
  9. doi request reprint Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients
    Akihito Tsubota
    Institute of Clinical Medicine and Research ICMR, Jikei University School of Medicine, Kashiwa, Chiba, Japan
    Liver Int 32:826-36. 2012
  10. ncbi request reprint High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 39:155-61. 2004

Collaborators

Detail Information

Publications74

  1. pmc Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C
    Akihito Tsubota
    Institute of Clinical Medicine and Research, The Jikei University School of Medicine, 163 1 Kashiwa shita, Kashiwa, Chiba 277 8567, Japan
    World J Gastroenterol 18:5879-88. 2012
    ..To construct formulae for predicting the likelihood of ribavirin-induced anemia in pegylated interferon α plus ribavirin for chronic hepatitis C...
  2. ncbi request reprint Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato, Tokyo, Japan
    J Gastroenterol Hepatol 20:426-32. 2005
    ..The purpose of the present paper was to identify factors that could influence the rapid progression of liver disease to hepatic failure, and assess the effects of lamivudine on serious disease...
  3. doi request reprint Bovine lactoferrin potently inhibits liver mitochondrial 8-OHdG levels and retrieves hepatic OGG1 activities in Long-Evans Cinnamon rats
    Akihito Tsubota
    Institute of Clinical Medicine and Research ICMR, Jikei University School of Medicine, Kashiwa, Chiba, Japan
    J Hepatol 48:486-93. 2008
    ..To assess the effect of lactoferrin on oxidative liver damage and its mechanism, we used Long-Evans Cinnamon (LEC) rats that spontaneously develop fulminant-like hepatitis and lethal hepatic failure...
  4. pmc Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study
    Akihito Tsubota
    Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163 1 Kashiwa shita, Kashiwa, Chiba 277 8567, Japan
    World J Gastroenterol 14:7220-4. 2008
    ..To assess the efficacy and advantages of 4-wk pegylated interferon alpha-2a (peg-IFN-alpha 2a) monotherapy for chronic hepatitis C patients with strong predictors of sustained virologic response (SVR)...
  5. doi request reprint IQGAP1 and vimentin are key regulator genes in naturally occurring hepatotumorigenesis induced by oxidative stress
    Akihito Tsubota
    Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163 1 Kashiwa shita, Kashiwa, Chiba 277 8567, Japan
    Carcinogenesis 31:504-11. 2010
    ..These findings enhance our understanding of the multistep hepatotumorigenesis and identification of target molecules for novel treatments...
  6. pmc Peginterferon and ribavirin treatment for hepatitis C virus infection
    Akihito Tsubota
    Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163 1 Kashiwa shita, Kashiwa, Chiba, Japan
    World J Gastroenterol 17:419-32. 2011
    ..The purpose of this review is to address some issues and epoch-making topics in the treatment of chronic HCV infection, and to discuss more optimal and highly individualized therapeutic strategies for HCV-infected patients...
  7. ncbi request reprint Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 75:27-34. 2005
    ..919. The results suggest that early monitoring of viral kinetics is a useful measure to predict virological response, and might facilitate development of rational and effective therapeutic strategies...
  8. ncbi request reprint Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Oncology 65:204-10. 2003
    ..Although hepatocellular carcinoma does develop after sustained response to interferon (IFN) in patients with chronic hepatitis C, details on the clinical prognosis have not been elucidated yet...
  9. doi request reprint Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients
    Akihito Tsubota
    Institute of Clinical Medicine and Research ICMR, Jikei University School of Medicine, Kashiwa, Chiba, Japan
    Liver Int 32:826-36. 2012
    ..Aims: To determine whether single nucleotide polymorphisms (SNPs) at the SLC29A1 gene could influence the probability of treatment response compared with other baseline and host genetic factors...
  10. ncbi request reprint High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 39:155-61. 2004
    ....
  11. ncbi request reprint Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 46:182-9. 2003
    ..However, the patient cohorts in such studies are relatively small...
  12. ncbi request reprint The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 38:315-21. 2003
    ..Genotype-dependent development of lamivudine resistance in hepatitis B virus (HBV) has not been reported...
  13. ncbi request reprint Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment
    Satoshi Mamori
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470 Tokyo, Japan
    J Gastroenterol 39:776-82. 2004
    ....
  14. ncbi request reprint Effect of acute self-limited hepatitis C virus (HCV) superinfection on hepatitis B virus (HBV)-related cirrhosis. Virological features of HBV-HCV dual infection
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 49:281-8. 2004
    ..Our results suggest that the impact of acute HCV infection on chronic HBV infection varies according to HBV virological state...
  15. ncbi request reprint Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies
    Norio Akuta
    Division of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 48:1654-7. 2003
  16. ncbi request reprint Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors
    Norio Akuta
    Division of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 37:831-6. 2002
    ..The mechanism of variable response to interferon (IFN) monotherapy in patients infected with HCV genotype 2a is still unclear. Here we investigated the response in a large group of patients infected with genotype 2a...
  17. ncbi request reprint Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 45:33-42. 2002
    ....
  18. ncbi request reprint Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470, Tokyo, Japan
    J Gastroenterol 39:969-74. 2004
    ..In Japan, there are few studies of long-term (more than 1 month) interferon (IFN) therapy for chronic hepatitis B (CHB). In this retrospective study, we investigated the efficacy and predictors of response to 6-month IFN therapy...
  19. ncbi request reprint Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop
    Yoshiyuki Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 46:164-70. 2003
    ..The long-term effects of lamivudine and the influence of YMDD mutants on the histology of chronic hepatitis B are not known...
  20. ncbi request reprint Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:355-61. 2004
    ....
  21. ncbi request reprint HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 70:355-60. 2003
    ..Our data suggested that during lamivudine therapy, core promoter and precore mutations do not influence HBeAg loss or seroconversion but may reduce the viral level upon HBeAg loss or seroconversion...
  22. ncbi request reprint Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Gastroenterol Hepatol 20:95-102. 2005
    ..Because the anti-carcinogenic effect and mechanism of interferon (IFN) in patients with hepatitis B virus (HBV)-related cirrhosis have not been elucidated, quantitative analysis of HBV-DNA concentration was carried out sequentially...
  23. doi request reprint Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus
    Masahiro Kobayashi
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo, 105 8470, Japan
    J Gastroenterol 43:63-70. 2008
    ..A phase II randomized controlled trial was conducted in patients with compensated liver cirrhosis to investigate the inhibitory effect of branched-chain amino acid (BCAA) granules for oral use (TK-98) on disease progression...
  24. ncbi request reprint Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 38:91-7. 2003
    ..Comparison of long-term prognosis in patients with chronic hepatitis B treated with lamivudine, with or without severe acute exacerbation (SAE)...
  25. ncbi request reprint Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 73:7-12. 2004
    ..The present study provides important information for the development of more effective and rational long-term lamivudine therapy for HBeAg-positive chronic hepatitis B patients infected exclusively with genotype..
  26. ncbi request reprint Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy
    Fumitaka Suzuki
    Research Institute for Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 37:922-7. 2002
    ..We aimed to treat patients with chronic hepatitis B on long-term treatment with lamivudine who developed lamivudine-resistant hepatitis B virus (HBV) mutants along with clinical relapses...
  27. doi request reprint Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients
    Mashu Aizawa
    Department of Gastroenterology and Hepatology, Kashiwa Hospital, Jikei University School of Medicine, Chiba, Japan
    J Med Virol 83:953-61. 2011
    ..The efficacy of LAM plus ADV combination therapy may be determined by viral response to the preceding LAM monotherapy...
  28. ncbi request reprint Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Intervirology 46:96-104. 2003
    ..To elucidate the influence of serum hepatitis B virus (HBV) load on hepatocellular carcinogenesis in cirrhotic patients, HBV-DNA was sequentially measured...
  29. ncbi request reprint Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 38:865-76. 2003
    ..Tumor recurrence is common after potentially curative ablation of hepatocellular carcinoma; therefore, the incidence of intrahepatic metastasis and multicentric carcinogenesis was evaluated...
  30. ncbi request reprint Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 37:824-30. 2002
    ..The aim of this study was to determine the changes in these regions in patients with chronic hepatitis B virus (HBV) infection treated with lamivudine for 5 years...
  31. ncbi request reprint Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 69:376-83. 2003
    ..Our results suggest that substitution patterns in NS5A in patients with low titer of HCV genotype 2a may affect their response to IFN, but the response to therapy may be affected by mechanisms other than substitutions in this region...
  32. ncbi request reprint Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 38:158-63. 2003
    ..We therefore assessed the efficacy of prolonged IFN therapy in patients with HCV-genotype 1b and a high virus load...
  33. ncbi request reprint Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus
    Tetsuya Hosaka
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:362-9. 2004
    ....
  34. ncbi request reprint YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine
    Marie Matsuda
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 74:361-6. 2004
    ....
  35. ncbi request reprint Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy
    Hitomi Sezaki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 38:493-500. 2003
    ..if IFN is expected to be efficacious on the basis of genotype of HCV-RNA level; even if there is acute exacerbation of type-C chronic hepatitis, IFN should be re-administered in the HCV-RNA level has dropped subsequently...
  36. ncbi request reprint Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, 1 3 1 Kajigaya, Takatsu ku, 213 8587 Kawasaki, Japan
    J Gastroenterol 39:844-50. 2004
    ..Because genotype A of hepatitis B virus (HBV) is not indigenous, there have been only few data on infection with it in Japan...
  37. ncbi request reprint Clinical features of hepatitis B virus genotype A in Japanese patients
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, 1 3 1 Kajigaya, Takatsu ku, Kawasaki 213 8587, Japan
    J Gastroenterol 38:656-62. 2003
    ..Hepatitis B virus (HBV) genotype A is predominant in northern Europe and central Africa. In the present study, we examined the clinical features associated with HBV genotype A disease in the Tokyo metropolitan area...
  38. ncbi request reprint Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    Intervirology 48:138-44. 2005
    ..The purpose of this clinical retrospective cohort study was to determine the most suitable ribavirin concentration on combination therapy of interferon (IFN)-ribavirin...
  39. ncbi request reprint Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:19-25. 2004
    ..We assessed whether sustained negativity for HCV-RNA over 24 or more months by long-term interferon (IFN) therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load or not...
  40. ncbi request reprint Precore wild-type hepatitis B virus with G1896 in the resolution of persistent hepatitis B virus infection
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 46:157-63. 2003
    ..Factors influencing the resolution of persistent hepatitis B virus (HBV) infection were sought for...
  41. ncbi request reprint [Therapeutic strategies for hepatitis C]
    Akihito Tsubota
    Institute of Clinical Medicine and Research, Jikei University School of Medicine
    Nihon Rinsho 62:441-7. 2004
  42. ncbi request reprint Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 39:455-60. 2004
    ..We assessed the efficacy of IFN retreatment for chronic hepatitis C patients who had a biochemical response (BR) after the first IFN therapy and reelevated ALT during follow up, by a case control study...
  43. ncbi request reprint Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection
    Akihito Tsubota
    Institute of Clinical Medicine and Research, Jikei University School of Medicine, Chiba, Japan
    Intervirology 47:335-41. 2004
    ..The aim of this study was to clarify potential factors, including benefit of lamivudine therapy, which could influence clinical course of the serious disease in an area of intermediate HBV endemicity...
  44. ncbi request reprint Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection
    Hitomi Sezaki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470, Tokyo, Japan
    J Gastroenterol 39:550-6. 2004
    ....
  45. ncbi request reprint Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 68:522-8. 2002
    ....
  46. ncbi request reprint Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis
    Hiromi Ooga
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470, Tokyo, Japan
    J Gastroenterol 39:1078-84. 2004
    ..The aim of this study was to evaluate the efficacy of lamivudine therapy in Japanese patients with cirrhosis, and to evaluate the clinical course after the emergence of YMDD mutants...
  47. ncbi request reprint Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy
    Norio Akuta
    Division of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 47:405-14. 2002
    ..We conclude that CSWT alone is a very short-term treatment of just three weeks that may be more effective for long-term clinical remission than CSWT followed by IFN-alpha in Japanese genotype C-dominant hepatitis B patients...
  48. ncbi request reprint Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: a multivariate analysis of a retrospective cohort of 593 patients with cirrhosis
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and the Memorial Institute for Medical Research, Tokyo, Japan
    Intervirology 45:71-8. 2002
    ..The influence of hepatitis C virus (HCV) subtypes on hepatocellular carcinogenesis was prospectively investigated...
  49. ncbi request reprint Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 20:570-6. 2005
    ..Virological and clinical differences between infections with subtypes Ba and Bj, however, are yet to be determined...
  50. ncbi request reprint Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy
    Norio Akuta
    Department of Gastroenterology and Liver Research Laboratory, Toranomon Hospital, Tokyo, Japan
    J Med Virol 71:504-10. 2003
    ..Large-scale studies of each mutant type should be conducted in the future to confirm these findings...
  51. ncbi request reprint Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis
    Yoshiyuki Suzuki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 39:649-53. 2004
    ....
  52. ncbi request reprint Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Kawasaki, Japan
    J Gastroenterol 37:35-9. 2002
    ....
  53. pmc Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy
    Tatsuo Kanda
    Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana, Chuo Ku, Chiba, Japan
    Int J Med Sci 10:43-9. 2013
    ..Attention should be paid to certain patients with unique features. Selection of patients according to their previous treatment could lead to optimal therapy in HCV genotype 2 treatment-experienced patients...
  54. ncbi request reprint Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma
    Masahiro Kobayashi
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Oncology 63:139-44. 2002
    ..Our study was designed to examine the efficacy of stepwise hook extension technique for radiofrequency ablation (RFA) therapy of hepatocellular carcinoma in a randomized controlled study...
  55. ncbi request reprint Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome
    Yoshiyuki Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 19:699-706. 2004
    ..The defining of the autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) overlap syndrome as a separate clinicopathological entity has been controversial and temporally and geographically subjective...
  56. ncbi request reprint A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo
    Intern Med 42:941-6. 2003
    ..The efficacy of thymosin alpha 1 (Talpha1) in patients with chronic hepatitis B still requires confirmation. We, therefore, evaluated the efficacy of therapy in patients with chronic hepatitis B...
  57. ncbi request reprint Overlap/switch to adefovir monotherapy for lamivudine-resistant patients who responded to combination therapy: a pilot controlled study
    Mashu Aizawa
    Department of Gastroenterology and Hepatology, Kashiwa Hospital, Kashiwa, Japan
    Intern Med 49:1067-72. 2010
    ..The aim of this study was to investigate the outcome of overlap/switch to adefovir dipivoxil (ADV) monotherapy for chronic hepatitis B (CHB) patients with lamivudine (LAM)-resistant HBV, who responded to LAM plus ADV combination therapy...
  58. doi request reprint Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b
    Masanori Atsukawa
    Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan
    J Gastroenterol Hepatol 28:51-6. 2013
    ..We focused on viral relapse that influences treatment outcome, and performed a post-hoc analysis by using data from a randomized controlled trial...
  59. doi request reprint Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients
    Tatsuo Kanda
    Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, 1 8 1 Inohana, Chuo Ku, Chiba, Japan
    Oncology 80:366-72. 2011
    ..Clinicians should regularly check for the possible development of HCC even in chronic hepatitis C patients under treatment...
  60. doi request reprint Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b
    Akihito Tsubota
    Institute of Clinical Medicine and Research ICMR, Jikei University School of Medicine, Kashiwa, Chiba, Japan Division of Gastroenterology and Hepatology, Kashiwa Hospital, Jikei University School of Medicine, Kashiwa, Chiba, Japan
    J Gastroenterol Hepatol 29:144-50. 2014
    ....
  61. pmc Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    Br J Clin Pharmacol 55:360-7. 2003
    ....
  62. doi request reprint Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b
    Kai Yoshizawa
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine Katsushika Medical Center, Tokyo, Japan
    J Med Virol 85:1180-90. 2013
    ..Together, we conclude that serum apoB-100 concentrations could predict virological response to Peg-IFN plus RBV combination therapy in patients infected with HCV G1b, especially in those with the rs8099917 hetero/minor genotype...
  63. doi request reprint Inorganic-organic magnetic nanocomposites for use in preventive medicine: a rapid and reliable elimination system for cesium
    Yoshihisa Namiki
    Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Kashiwa, Japan
    Pharm Res 29:1404-18. 2012
    ..To investigate the potential use of Prussian blue-coated magnetic nanoparticles, termed "Prussian blueberry", to bring about the magnetic elimination of cesium...
  64. ncbi request reprint Detection of sentinel nodes by a novel red-fluorescent dye, ATX-S10Na (II), in an orthotopic xenograft rat model of human gastric carcinoma
    Tomoki Koyama
    Institute of Clinical Medicine and Research ICMR, Jikei University School of Medicine, 163 1 Kashiwa shita, Kashiwa, Chiba 277 8567, Japan
    Lasers Surg Med 39:76-82. 2007
    ..We developed a new imaging system to detect sentinel nodes (SNs) using a novel fluorescent tracer, ATX-S10Na(II), and investigated its usefulness in an animal model...
  65. ncbi request reprint Early apoptosis and cell death induced by ATX-S10Na (II)-mediated photodynamic therapy are Bax- and p53-dependent in human colon cancer cells
    Makoto Mitsunaga
    Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163 1 Kashiwa shita, Kashiwa, Chiba 277 8567, Japan
    World J Gastroenterol 13:692-8. 2007
    ..To investigate the roles of Bax and p53 proteins in photosensitivity of human colon cancer cells by using lysosome-localizing photosensitizer, ATX-S10Na (II)...
  66. pmc A mutation of the start codon in the X region of hepatitis B virus DNA in a patient with non-B, non-C chronic hepatitis
    Kiyotaka Fujise
    Kiyotaka Fujise, Keiko Tatsuzawa, Akihito Tsubota, Minoru Niiya, Hisao Tajiri, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kashiwa Hospital, The Jikei University School of Medicine, Chiba 277 8567, Japan
    World J Hepatol 3:56-60. 2011
    ..It is assumed that a mutation at the start codon in the X region may be the reason why HBV markers are negative in some cases of hepatitis that involve occult HBV infection...
  67. doi request reprint Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C
    Yoshio Aizawa
    Division of Gastroenterology and Hepatology, Jikei University Aoto Hospital, Tokyo, Japan
    Mol Cell Biochem 360:9-14. 2012
    ..In particular, serum apoB-100 concentration might be an informative marker for judging changes in HCV-associated intracellular lipoprotein metabolism in patients carrying the rs8099917 responder genotype...
  68. ncbi request reprint Highly active antiretroviral therapy improved persistent lamivudine-resistant viremia in acute hepatitis B virus genotype Ae infection with coinfection of human immunodeficiency virus
    Mashu Aizawa
    Department of Gastroenterology and Hepatology, Kashiwa Hospital, Tokyo, Japan
    Hepatol Res 40:229-35. 2010
    ....
  69. ncbi request reprint [Mechanism of hepatitis B virus infection in human hepatocytes]
    Akihito Tsubota
    Institute of Clinical Medicine and Research, Jikei University School of Medicine
    Nihon Rinsho 62:58-61. 2004
  70. doi request reprint A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery
    Yoshihisa Namiki
    Institute of Clinical Medicine and Research, The Jikei University School of Medicine, 163 1 Kashiwa shita, Kashiwa, Chiba, Japan
    Nat Nanotechnol 4:598-606. 2009
    ..By delivering an optimized sequence of a silencing RNA that targets the epidermal growth factor receptor of tumour vessels, the intended therapeutic benefit was achieved with no evident adverse immune reaction or untoward side effects...
  71. ncbi request reprint [Genotyping of hepatitis B virus genome by RFLP]
    Akihito Tsubota
    Institute of Clinical Medicine and Research, Jikei University School of Medicine
    Nihon Rinsho 62:160-2. 2004
  72. ncbi request reprint How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection?
    Akihito Tsubota
    J Gastroenterol Hepatol 21:1769-71. 2006
  73. ncbi request reprint Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C
    Shintaro Takaki
    Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1 2 3 Kasumi, Minami Ku, 734 8551, Hiroshima, Japan
    J Gastroenterol 39:668-73. 2004
    ..Recent studies indicate that combination therapy with ribavirin and interferon alfa2b (IFNAlpha2b) is effective for chronic hepatitis C virus (HCV) infection. However, reversible hemolytic anemia is a common side effect of this therapy...
  74. ncbi request reprint Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine
    Marie Matsuda
    Research Institute for Hepatology, Toranomon Branch Hospital, 1 3 1 Kajigaya, Takatsu ku, Kawasaki 213 8587, Japan
    J Gastroenterol 39:34-40. 2004
    ..However, recent studies have reported lamivudine-resistant viruses in patients with CH-B before such treatment. The aim of this study was to investigate whether YMDD mutants occur in nature...